WO2004108960A3 - Methods for predicting drug efficacy in patients afflicted with hypertension - Google Patents

Methods for predicting drug efficacy in patients afflicted with hypertension Download PDF

Info

Publication number
WO2004108960A3
WO2004108960A3 PCT/IB2004/001947 IB2004001947W WO2004108960A3 WO 2004108960 A3 WO2004108960 A3 WO 2004108960A3 IB 2004001947 W IB2004001947 W IB 2004001947W WO 2004108960 A3 WO2004108960 A3 WO 2004108960A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
expression profile
hypertension
sample
drug efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/001947
Other languages
French (fr)
Other versions
WO2004108960A2 (en
Inventor
Hakon Hakonarson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Priority to EP04736099A priority Critical patent/EP1633885A2/en
Priority to CA002527323A priority patent/CA2527323A1/en
Priority to AU2004245762A priority patent/AU2004245762B9/en
Publication of WO2004108960A2 publication Critical patent/WO2004108960A2/en
Publication of WO2004108960A3 publication Critical patent/WO2004108960A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods are disclosed for predicting the efficacy of a drug for treating hypertension in a patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile from the sample in the absence and presence of in vitro modulation of the cells with specific mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarity between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating hypertension in the patient.
PCT/IB2004/001947 2003-06-09 2004-06-04 Methods for predicting drug efficacy in patients afflicted with hypertension Ceased WO2004108960A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04736099A EP1633885A2 (en) 2003-06-09 2004-06-04 Methods for predicting drug efficacy in patients afflicted with hypertension
CA002527323A CA2527323A1 (en) 2003-06-09 2004-06-04 Methods for predicting drug efficacy in patients afflicted with hypertension
AU2004245762A AU2004245762B9 (en) 2003-06-09 2004-06-04 Methods for predicting drug efficacy in patients afflicted with hypertension

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47708703P 2003-06-09 2003-06-09
US60/477,087 2003-06-09

Publications (2)

Publication Number Publication Date
WO2004108960A2 WO2004108960A2 (en) 2004-12-16
WO2004108960A3 true WO2004108960A3 (en) 2005-07-14

Family

ID=33511837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001947 Ceased WO2004108960A2 (en) 2003-06-09 2004-06-04 Methods for predicting drug efficacy in patients afflicted with hypertension

Country Status (5)

Country Link
US (1) US20050032096A1 (en)
EP (1) EP1633885A2 (en)
AU (1) AU2004245762B9 (en)
CA (1) CA2527323A1 (en)
WO (1) WO2004108960A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US6893828B2 (en) * 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2002053769A2 (en) * 2000-12-29 2002-07-11 Rudolf Wiesner Dna chip for performing causal diagnosis of hypertension
WO2002070742A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
WO2003020220A2 (en) * 2001-08-30 2003-03-13 Emory University Mitochondrial biology expression arrays
WO2003021261A2 (en) * 2001-09-06 2003-03-13 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US20030096782A1 (en) * 2001-09-11 2003-05-22 The Regents Of The University Of Colorado Expression profiling in the intact human heart
WO2003083140A2 (en) * 2002-03-22 2003-10-09 St.Jude Children's Research Hospital, Inc. Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US6893828B2 (en) * 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2002053769A2 (en) * 2000-12-29 2002-07-11 Rudolf Wiesner Dna chip for performing causal diagnosis of hypertension
WO2002070742A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
WO2003020220A2 (en) * 2001-08-30 2003-03-13 Emory University Mitochondrial biology expression arrays
WO2003021261A2 (en) * 2001-09-06 2003-03-13 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US20030096782A1 (en) * 2001-09-11 2003-05-22 The Regents Of The University Of Colorado Expression profiling in the intact human heart
WO2003083140A2 (en) * 2002-03-22 2003-10-09 St.Jude Children's Research Hospital, Inc. Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis

Also Published As

Publication number Publication date
AU2004245762B2 (en) 2008-02-28
CA2527323A1 (en) 2004-12-16
WO2004108960A2 (en) 2004-12-16
AU2004245762A1 (en) 2004-12-16
US20050032096A1 (en) 2005-02-10
EP1633885A2 (en) 2006-03-15
AU2004245762B9 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
WO2003021261A3 (en) Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
WO2001078652A3 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2003041562A3 (en) Molecular cancer diagnosis using tumor gene expression signature
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
NZ593227A (en) Gene expression markers (MYBL2) for colorectal cancer prognosis
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2004013310A3 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2004031412A3 (en) Method for diagnosing pancreatic cancer
WO2003014303A3 (en) Molecular interactions in cells
EP1539930A4 (en) Multi-step method for the differentiation of insulin positive, glucose
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
AU2003299864A1 (en) Sirna compounds and methods for the downregulation of gene expression
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
AU2003258247A1 (en) Medical decision support systems utilizing gene expression and clinical information and method for use
WO2004038381A3 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2005117938A3 (en) Methods of treating ocular conditions
WO2005001138A3 (en) Breast cancer survival and recurrence
WO2002061144A8 (en) Brain tumor diagnosis and outcome prediction
WO2002098355A3 (en) Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
WO2004108960A3 (en) Methods for predicting drug efficacy in patients afflicted with hypertension
WO2005003370A3 (en) Methods for enhancing gene expression analysis
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2005121374A3 (en) Molecular analysis of hair follicles for disease
TW200510011A (en) A method for regeneration of bone
WO2004070018A3 (en) Vegf-b and pdgf modulation of stem cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004245762

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2527323

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004245762

Country of ref document: AU

Date of ref document: 20040604

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004245762

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004736099

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004736099

Country of ref document: EP